Solar-simulated UV-irradiation causes changes in the enzymic antioxidant defence system in the human epidermis. The aim of this study was to investigate the effects on the skin lipid peroxidation and clinical improvement in vitiligo patients treated with PUVA. The first group of patients was treated for six months with psoralen plus UV-A (n = 15). The second group of patients was treated for six months with psoralen plus UV-A vs vitamin E (900 IU daily perorally) (n = 15). There was no significant difference in the clinical improvement between the group of patients who were treated with PUVA and vitamin E and the group of patients treated with PUVA alone (p > 0.05). Statistical analysis revealed a significant difference between the levels of lipoperoxides before and after treatment in the first group (p < 0.05), but there was no significant difference between the levels of lipoperoxides before and after treatment in the second group (p > 0.05). According to our results, vitamin E may prevent oxidative distress resulting from PUVA therapy, but does not affect the clinical improvement of the vitiligo lesions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Preclinical evaluation of the efficacy and safety of AAV8-TNAP-D10 in Alpl-/- and AlplPrx1/Prx1 mouse models for the treatment of early and late-onset hypophosphatasia.
J Bone Miner Res
January 2025
Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.
We previously documented successful resolution of skeletal and dental disease in the infantile and late-onset murine models of hypophosphatasia (HPP), with a single injection of an adeno-associated serotype 8 vector encoding mineral-targeted TNAP (AAV8-TNAP-D10). Here, we conducted dosing studies in both HPP mouse models. A single escalating dose from 4x108 up to 4x1010 (vg/b) was intramuscularly injected into 4-day-old Alpl-/- mice (an infantile HPP model) and a single dose from 4x106 up to 4x109 (vg/b) was administered to 8-week-old AlplPrx1/Prx1 mice (a late-onset HPP model).
View Article and Find Full Text PDFCurrent Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.
Drug Dev Res
February 2025
South University School of Pharmacy, Savannah, Giorgia, USA.
KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.
View Article and Find Full Text PDFMixed neuroendocrine-non-neuroendocrine neoplasm of the colon treated with laparoscopic resection and adjuvant chemotherapy: a case report.
Clin J Gastroenterol
January 2025
Department of Surgery, Shizuoka Medical Center NHO, 762-1, Nagasawa, Shimizu, Sunto, Shizuoka, 411-8611, Japan.
Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) of the colon is rare with a poor prognosis. Since the first description of a mixed neoplasm 100 years ago, the nomenclature has evolved, most recently with the 2022 World Health Organization (WHO) classification system. We describe our experience of a case of locoregionally advanced MiNEN of the descending colon treated with curative laparoscopic resection and adjuvant chemotherapy.
View Article and Find Full Text PDFDepression and anxiety in people with kidney disease: understanding symptom variability, patient experience and preferences for mental health support.
J Nephrol
January 2025
School of Life and Medical Sciences, University of Hertfordshire, College Lane Campus, Hatfield, UK.
Article Synopsis
- The study investigates the prevalence and factors related to depression and anxiety among individuals with chronic kidney disease (CKD) in the UK, revealing that significant portions experience these mental health issues.
- Participants completed an online survey that assessed mental health history and treatment preferences, finding that over half had a history of diagnosed depression and many preferred in-person support.
- The results indicated that certain demographics, including age and gender, as well as factors like self-efficacy and current treatment, were significantly related to the levels of depression and anxiety symptoms, but differences in symptoms were not influenced by the kidney service centers’ location or size.
The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.
Breast Cancer Res Treat
January 2025
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- The study investigates how changes in the Ki67 biomarker before and after neoadjuvant chemotherapy (NACT) affect survival in patients with triple-negative breast cancer (TNBC).
- Among 1,777 TNBC patients analyzed, most showed a decrease in tumor size and Ki67 levels after NACT, though many had no change or experienced treatment discontinuation.
- Patients with unchanged Ki67 had significantly worse overall and disease-specific survival compared to those with decreased Ki67, emphasizing the need for personalized treatment strategies based on ongoing monitoring of this biomarker.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!